Latest news with #AlzeCurePharma
Yahoo
16-07-2025
- Business
- Yahoo
AlzeCure Receives Additional Subscription Commitments of Approximately SEK 7 million in the Ongoing Rights Issue
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, WITHIN OR INTO THE AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES, RUSSIAN FEDERATION, BELARUS, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, DISTRIBUTION OR RELEASE WOULD BE CONTRAVENING TO ANY APPLICABLE RULES. ADDITIONAL RESTRICTIONS ARE APPLICABLE, PLEASE SEE "IMPORTANT INFORMATION" IN THE END OF THIS PRESS RELEASE. STOCKHOLM, SE / / July 16, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB ("AlzeCure" or the "Company") has received additional subscription commitments of SEK 7 million from a group of qualified investors in the Company's ongoing rights issue announced on June 16, 2025 (the "Rights Issue"). Should the issue be oversubscribed, the Company intends to utilize the remaining portion of the Over-Allotment Option, following the previously announced additional subscription commitment, to accommodate these subscriptions to the greatest extent possible. In addition to previously entered subscription commitments, a group of qualified investors have committed to subscribe for shares amounting to approximately SEK 7 million, corresponding to about 14 percent of the Rights Issue. The subscription commitments are based on the same terms as for other investors, i.e. no remuneration. In the event the issue is oversubscribed and the allocation under these additional subscription commitments cannot be fully allocated, the Company intends to utilize the remaining portion of the Over-Allotment Option of around SEK 5 million to accommodate theses subscription to the greatest extent possible in accordance with the principle that allocation under the overallotment option shall primarily be made to strategic and/or qualified investors. Following these additional subscription commitments, the total amount of subscription commitments entered into amounts to approximately SEK 32 million, corresponding to around 66 percent of the total amount of the Rights Issue of approximately SEK 48.5 million, with an over-allotment option of SEK 10 million. "At AlzeCure Pharma, we are very pleased with the interest and support we are seeing for the share issue, both from existing major shareholders and new investors. This demonstrates confidence in the share issue and the plans it is intended to finance, which primarily include preparations for the upcoming Phase 2 study in Alzheimer's patients with NeuroRestore ACD856 - a project for which we have secured funding from the European Innovation Council. We are very proud of this support, which can also be seen as a validation of the project," says Martin Jönsson, CEO of AlzeCure. Additional subscription commitments: Investor Subscription commitment, SEK Jan Poulsen 2,000,000 Niklas Estensson 1,000,000 Christian Månsson 1,000,000 Rose-Marie Karlsson 1,000,000 Alexander Schoeneck 1,000,000 AV Linbo Invest AB 660,000 Johan Wiklund 308,000 TOTAL 6,968,000 The subscription period for the share issue runs through July 22. More information is available at: Advisors AlzeCure has engaged Zonda Partners AB and Synch Advokat AB as financial and legal advisors, respectively, in connection with the Rights Issue. In connection with the additional subscription commitment addressed in this press release, Corpura Fondkommission AB has also acted as joint bookrunner. Important information The information in this press release does not contain or constitute an offer to acquire, subscribe for, or otherwise trade in shares, subscription warrants, or other securities in AlzeCure. No action has been taken, and no actions will be taken, to permit a public offering in any jurisdiction other than Sweden. Any invitation to eligible persons to subscribe for shares in AlzeCure will only be made through the supplementary Information Document published by AlzeCure on 7 July 2025. The information in this press release may not be announced, published, or distributed, directly or indirectly, in or into Australia, Hong Kong, Japan, Canada, New Zealand, Singapore, South Africa, the United States, Belarus, Russia, South Korea, Switzerland, or any other jurisdiction where such action would be unlawful, subject to legal restrictions, or would require actions other than those required under Swedish law. Any failure to comply with these restrictions may constitute a violation of applicable securities laws. For more information, please contact Martin Jönsson, CEOTel: +46 707 86 94 About AlzeCure Pharma AB (publ) AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless. NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease and comprises two drug candidates. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development through an early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies. FNCA Sweden AB is the company's Certified Adviser. For more information, please visit Attachments AlzeCure Receives Additional Subscription Commitments of Approximately SEK 7 million in the ongoing Rights Issue SOURCE: AlzeCure Pharma View the original press release on ACCESS Newswire
Yahoo
16-06-2025
- Business
- Yahoo
Notice To Extraordinary General Meeting In Alzecure Pharma AB
STOCKHOLM, SE / / June 16, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - The shareholders of AlzeCure Pharma AB are hereby summoned to an extraordinary general meeting to be held on Wednesday 2 July 2025 at 15:30 CEST at the offices of Synch Advokat, Birger Jarlsgatan 6, Stockholm. NOTIFICATION ETC. Shareholders who wish to participate in the general meeting must • be entered as a shareholder in the share register maintained by Euroclear Sweden AB on Tuesday 24 June 2025; and • notify the company of their intention to participate no later than Thursday 26 June 2025. Notification of participation shall be made in writing by e-mail to The notification should state name, personal ID number or corporate registration number, address and telephone number. Any accompanying advisors (maximum two) should be notified in the same manner. Shareholders whose shares are nominee-registered must, in order to be entitled to participate in the general meeting, temporarily register the shares in their own name, so that the shareholder is entered into the share register maintained by Euroclear Sweden AB as of the record date Tuesday 24 June 2025. Such registration may be temporary (so-called voting registration). Shareholders who wish to register shares in their own name must, in accordance with the respective nominee's procedures, request that the nominee effects such voting registration. Voting registration requested by shareholders in such time that the registration has been completed by Thursday 26 June 2025 will be taken into account in the preparation of the share register. Shareholders represented by proxy shall issue a written and dated power of attorney for the proxy. A person representing a legal entity shall present a certificate of registration (or equivalent authority document) evidencing that the individuals who have signed the power of attorney are authorized signatories for the shareholder. To facilitate entry to the general meeting, the original power of attorney (and any authorization documents) should be sent to the company together with the notification of participation, well in advance of the meeting. Proxy forms are available on the company's website, PROPOSED AGENDA Election of chairman of the meeting Preparation and approval of the voting register Approval of the agenda Election of one or two persons to verify the minutes Determination of whether the meeting has been duly convened Resolution to approve the Board of Directors' resolution on a new share issue Closing of the meeting. PROPOSALS Item 6: Resolution to approve the Board of Directors' resolution on a new share issue The Board of Directors resolved on Wednesday 16 June 2025 on a new share issue, subject to the general meeting's approval. The resolution, which the extraordinary general meeting is proposed to approve, includes the following principal terms: The company's share capital shall be increased by a maximum of SEK 551,845 through a new share issue of a maximum of 22,073,800 shares The company's shareholders shall have preferential rights to subscribe for the new shares, whereby one (1) existing share in the company shall entitle to one (1) subscription right and four (4) subscription rights shall entitle to subscription for one (1) share. The record date for determining the shareholders entitled to subscribe for new shares with preferential rights shall be 4 July 2025. The subscription price shall be SEK 2.20 per share. Subscription for shares shall take place during the period from and including 8 July 2025 to and including 22 July 2025. Subscription of shares with preferential rights (i.e., by exercise of subscription rights) shall be made by simultaneous payment. Subscription of shares without preferential rights (i.e., without subscription rights) shall be made on a subscription list. The Board of Directors shall be entitled to extend the subscription period. Payment for shares subscribed without preferential rights (i.e., without subscription rights) shall be made no later than three banking days from the issuance of the allocation notice (settlement note). However, the Board shall be entitled to extend the payment period. Payment for subscribed shares shall be made in cash. It is noted, however, that the Board may allow set-off in accordance with Chapter 13, Section 41 of the Swedish Companies Act. Any share premium shall be transferred to the unrestricted share premium reserve. To the extent not all shares are subscribed for by exercise of subscription rights, the Board shall, within the framework of the maximum amount of the issue, resolve on allotment of shares subscribed for without subscription rights, whereby allotment shall be made primarily to those who have also subscribed for shares by exercise of subscription rights and, if they cannot be allotted all shares subscribed for, in proportion to their subscription by exercise of subscription rights and, to the extent this is not possible, by drawing lots, and secondarily to others who have subscribed for shares in the issue without subscription rights and, if they cannot be allotted all shares subscribed for, in proportion to the number of shares each has subscribed for and, to the extent this is not possible, by drawing lots. The new shares shall carry entitlement to dividends for the first time on the record date for dividends that occurs immediately after the new shares have been entered in the share register maintained by Euroclear Sweden AB. The Board of Directors, or the person appointed by the Board, shall be authorised to make such minor adjustments to the resolution as may be required in connection with registration of the resolution with the Swedish Companies Registration Office, Euroclear Sweden AB or due to other formal requirements. INFORMATION AT THE GENERAL MEETING The shareholders are reminded of their right to request information from the Board of Directors and the CEO in accordance with Chapter 7, Section 32 of the Swedish Companies Act PROCESSING OF PERSONAL DATA For information on how your personal data is processed, please refer to DOCUMENTS The Board of Directors' complete resolution, together with documentation pursuant to Chapter 13, Section 6 of the Swedish Companies Act, is available to shareholders and will be sent immediately and free of charge to shareholders who request it and provide their postal address. Such request shall be made in writing to Hälsovägen 7, 141 57 Huddinge or by e-mail to __________________ Stockholm, June 2025 AlzeCure Pharma AB (publ)The Board of Directors This is an office translation of the Swedish original. In case of differences the Swedish original text shall prevail. For more information, please contact Martin Jönsson, CEOTel: +46 707 86 94 About AlzeCure Pharma AB (publ) AlzeCure ® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore ® , Alzstatin ® and Painless. NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease and is being prepared for phase 2. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain with positive phase 2 results, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development through an early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies. FNCA Sweden AB is the company's Certified Adviser. For more information, please visit . Attachments NOTICE TO EXTRAORDINARY GENERAL MEETING IN ALZECURE PHARMA ABNOTICE TO EXTRAORDINARY GENERAL MEETING IN ALZECURE PHARMA AB SOURCE: AlzeCure Pharma View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16-06-2025
- Business
- Yahoo
AlzeCure Carries out a Rights Issue of Approximately SEK 48.5 million
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, WITHIN OR INTO THE RUSSIAN FEDERATION, BELARUS, AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, DISTRIBUTION OR RELEASE WOULD BE CONTRAVENING TO ANY APPLICABLE RULES. ADDITIONAL RESTRICTIONS ARE APPLICABLE, PLEASE SEE "IMPORTANT INFORMATION" IN THE END OF THIS PRESS RELEASE. STOCKHOLM, SE / / June 16, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB ("AlzeCure" or the "Company"), a pharmaceutical company that develops a broad portfolio of small molecule drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, today announces that the Board of Directors has resolved on a new share issue of approximately SEK 48.5[1] million with preferential rights for existing shareholders (the "Rights Issue"). The Rights Issue is subject to approval by an extraordinary general meeting to be held on 2 July 2025. The record date for participation in the Rights Issue is 4 July 2025. According to the terms of the Rights Issue, one (1) existing share in AlzeCure entitles the holder to one (1) subscription right, and four (4) subscription rights entitle the holder to subscribe for one (1) new share at a subscription price of SEK 2.20 per share. The Rights Issue is secured to approximately 42 percent through subscription undertakings from existing shareholders, including members of the Company's management and Board of Directors. In order to enable additional capital raise, the Board may also resolve on the exercise of an over-allotment option of up to approximately SEK 10 million (the "Over-Allotment Option"). If the Over-Allotment Option is exercised in full, the total gross proceeds may amount to approximately SEK 58.5 million. A separate notice to the extraordinary general meeting will be published. "We are very pleased that all of our major existing shareholders, as well as all members of the Board of Directors, support our exciting projects by committing to subscribe for their respective pro-rata shares in the Rights Issue, alongside myself. Given this strong support and considering our upcoming capital needs, we are in the fortunate position of not requiring external guarantors for this transaction, which makes the Rights Issue cost-efficient. The proceeds will be used to prepare for the upcoming Phase 2 study with ACD856 in Alzheimer's patients, which is also co-financed by the European Innovation Council (EIC). In addition to the EUR 2.5 million grant from EIC, we have also received an offer for further potential funding through an EIC equity investment in AlzeCure, which we are currently evaluating. The proceeds will also support continued business development efforts, with a focus on out-licensing ACD440 following the positive feedback from the FDA regarding a Phase 2b/3 registration study, which adds value for our shareholders," says Martin Jönsson, CEO of AlzeCure Pharma AB. Background and rationale for the Rights IssueAlzeCure® is a Swedish pharmaceutical company focused on developing novel, innovative small molecule therapies for the treatment of severe diseases affecting the central nervous system, such as Alzheimer's disease and pain - indications for which current treatment options remain very limited. The Company is listed on Nasdaq First North Premier Growth Market and is developing several drug candidates in parallel across its three research platforms: NeuroRestore®, Alzstatin®, and Painless. The medical need in the Alzheimer's space remains significant, with the number of patients expected to triple over the next 30 years. [2] Studies show that only 5 to 8 percent of Alzheimer's patients referred to memory clinics are suitable for treatment with the recently approved antibody-based therapies.[3] Despite this, such therapies are expected to generate peak annual sales exceeding SEK 100 billion. NeuroRestore ACD856 has shown potent memory- and learning-enhancing effects in preclinical models and new studies also indicate disease-modifying potential. ACD856 has shown neuroprotective and anti-inflammatory properties and is currently being prepared for Phase II.[4] Alzstatin ACD680 has demonstrated a strong ability to reduce the production of the toxic Ab42 protein - the building block of the amyloid plaques that are so characteristic of Alzheimer's disease. Together, these results suggest that AlzeCure's two Alzheimer's projects, NeuroRestore and Alzstatin, have the potential to become important stand-alone therapies as well as to complement antibody-based treatments, thereby addressing a significant unmet medical need. The Painless platform, which includes the pain projects ACD440 and TrkA-NAM, is also advancing. ACD440, a topically administered gel for neuropathic pain, has previously shown a statistically significant analgesic effect in patients with chronic nerve pain. Preparations are ongoing for the continued clinical development of ACD440, for which the Company recently received positive feedback from the FDA on a planned Phase 2b/3 registration study in erythromelalgia. TrkA-NAM, a project targeting pain associated with knee osteoarthritis, has this year demonstrated potent analgesic effects in preclinical models and also shown joint-protective properties. Both projects address areas with high medical need. In the United States alone, approximately 50 million adults are estimated to suffer from chronic severe pain - more than the total number of people affected by diabetes, heart disease and cancer combined.[5] Data from Europe show similar trends, and the associated healthcare and societal costs are estimated to amount to 3-10 percent of GDP.[6] Due to the risk of misuse, overdose, and secondary harm, opioids are typically avoided in pain treatment, highlighting the need for new non-opioid treatment options. All of the Company's projects are progressing strongly. The Company is engaged in multiple discussions regarding potential licensing or collaboration agreements across its pipeline. The scientific value of the programs is also validated by the significant, highly competitive EIC Accelerator grant of EUR 2.5 million awarded to the NeuroRestore ACD856 project. In addition, the Company has been offered the opportunity to receive further funding through the EIC Fund, subject to additional due diligence and certain conditions. Against this backdrop, the Board considers it strategically valuable to strengthen the Company's cash position at this stage, in order to improve the Company's negotiating position and to fully leverage the opportunities presented through the EIC. The net proceeds from the Rights Issue will be used for the following purposes: Continued safety and toxicology studies, as well as preparations for Phase I clinical trials for the Alzheimer's project Alzstatin, aimed at early preventive treatment. Initiation of preparatory activities for the upcoming Phase 2a clinical trial in patients with early Alzheimer's for NeuroRestore ACD856, designed to enhance memory and learning. This study is also co-funded by the European Innovation Council. Continued safety and toxicology studies, as well as preparations for Phase I clinical trials for TrkA-NAM ACD137, targeting pain treatment of knee osteoarthritis. Intensified business development efforts aimed at achieving out-licensing and/or partnerships for the Company's drug candidates, with a primary focus on the pain program ACD440. These efforts are intended to support long-term financing and development opportunities for the Company's project portfolio. Summary of the Rights Issue One (1) existing share in AlzeCure held on the record date of 4 July 2025 entitles the holder to one (1) subscription right. Four (4) subscription rights entitle the holder to subscribe for one (1) newly issued share. The subscription price is SEK 2.20 per share. Through the Rights Issue, AlzeCure may raise up to approximately SEK 48.5 million before deduction of issue-related costs (estimated at approximately SEK 2.9 million). The subscription period runs from 8 July 2025 to 22 July 2025. Subscription rights that are not exercised during the subscription period will become invalid and lose their value. Trading in subscription rights is expected to take place on Nasdaq First North Premier Growth Market between 8-17 July 2025. The Board's resolution on the Rights Issue is conditional upon approval by the extraordinary general meeting to be held on 2 July 2025. The notice convening the extraordinary general meeting will be published in connection with this press release. The Company has received subscription undertakings from existing shareholders, board members and management to subscribe for shares corresponding to approximately SEK 20 million, or about 42 percent of the Rights Issue. These undertakings are not secured by bank guarantees, blocked funds, pledges or similar arrangements. Based on the authorization granted at the Annual General Meeting on 14 May 2025, the Board also has the option to utilize an over-allotment option of SEK 10 million. The over-allotment option is intended primarily for strategic and/or qualified investors who apply to subscribe in the Rights Issue but do not receive full allocation. Any remaining allocation will follow the principles applicable to the Rights Issue. Full terms and conditions of the Rights Issue as well as additional information about the Company will be set out in the Annex IX, prepared and published in accordance with Article 1.4 i) db) of the Prospectus Regulation, which is expected to be published on or around 4 July 2025. The timetable is preliminary and subject to change. Preliminary timetable for the Rights Issue2 July 2025 - Extraordinary general meeting 2 July 2025 - Last day of trading in shares including the right to receive subscription rights 3 July 2025 - First day of trading excluding the right to receive subscription rights 4 July 2025 - Record date for participation in the Rights Issue 4 July 2025 - Publication of the Annex IX 8-22 July 2025 - Subscription period 8-17 July 2025 - Trading in subscription rights on Nasdaq First North Premier Growth Market 24 July 2025 - Announcement of the outcome of the Rights Issue Changes in share capital, number of shares and dilutionThrough the Rights Issue, the Company's share capital may increase by a maximum of SEK 551,845, from SEK 2,207,380 to SEK 2,759,225, through the issuance of up to 22,073,800 new shares. As a result, the number of shares may increase from 88,295,200 to a maximum of 110,369,000 shares. For shareholders who do not participate in the Rights Issue, this corresponds to a dilution effect of approximately 20 percent of the capital and votes in the Company, assuming full subscription. Over-Allotment OptionTo enable additional capital inflow in the event the Rights Issue is oversubscribed, the Board may resolve to utilize the Over-Allotment Option. Shares issued under the Over-Allotment Option will be primarily allocated to strategic and/or qualified investors who apply to subscribe in the Rights Issue without receiving full allocation. Any remaining shares will be allocated in accordance with the principles of the Rights Issue. If fully exercised, the Over-Allotment Option may raise an additional SEK 10 million. This would result in the issuance of an additional 4,545,455 shares at the subscription price of SEK 2.20 per share. The Board intends to resolve on the Over-Allotment Option based on the existing issuance authorization. If fully utilized, the Over-Allotment Option would increase the share capital by SEK 113,636, corresponding to additional dilution of approximately 3 percent. The total dilution, including the Rights Issue and the Over-Allotment Option, would thus amount to approximately 23 percent. Approval at the Extraordinary General MeetingTo obtain shareholder approval of the Board's resolution on the Rights Issue, the Company will convene an extraordinary general meeting, scheduled to be held on 2 July 2025. A separate notice convening the meeting will be published. AdvisorsAlzeCure has engaged Zonda Partners AB and Synch Advokat AB as financial and legal advisors, respectively, in connection with the Rights Issue. Important informationThe information in this press release does not contain nor constitute an offer to acquire, subscribe for or in any other way trade with shares, warrants or other securities in AlzeCure. No measures have been taken and no measures will be taken in order to allow for an offer to the public in any other jurisdictions than Sweden. Offer to for the relevant persons to subscribe for shares in AlzeCure will only be made through the Annex IX which AlzeCure expects will be published around July 4, 2025. The information in this press release may not be made public, be published or distributed, directly or indirectly, within or to USA, Belarus, Russia, Australia, Hongkong, Japan, New Zeeland, Switzerland, Singapore, South Africa or any other jurisdiction where such action would be illegal, subject to legal restrictions or require other actions than what is stipulated under Swedish law. Any actions not in compliance with these instructions may constitute a violation against applicable securities regulation. No shares or other securities in AlzeCure have been registered, and no shares or other securities will be registered, under United States Securities Act of 1933 ("Securities Act") as in force from time to time or under the securities laws in any state or other jurisdiction in the US and may not be offered, sold or in any other way transferred, directly or indirectly, in or to the US, except for pursuant to an applicable exemption from, or in a transaction not subject to, the registration rules in the Securities Act and in compliance with the securities regulations in the relevant state or other jurisdiction in the US. This communication is distributed and aimed for only persons in Great Britain who are (i) professional investors under Article 19(5) in UK Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 ("Order") as in force from time to time or (ii) subjects with a high net wealth and other persons to whom this message can be legally addressed, who are subject to Article 49(2)(a)-(d) in the Order (all those persons referred to as "Relevant Persons"). Persons who are not Relevant Persons may not act on or rely on the information in this communication. An investment or investment action referred to in this communication is only possible for Relevant Persons and will only be closed with Relevant Persons. Persons who distribute this communication must themselves make certain that such distribution is allowed. Forward-looking statementsThis press release contains forward-looking statements regarding the Company's intentions, assessments, or expectations in respect of the Company's future results, financial position, liquidity, development, prospects, expected growth, strategies and possibilities as well as the market within which the Company operates. Forward-looking statements are statements which do not refer to historical facts and which typically contain words such as "considers", "expects", "predicts", "intends to", "estimates", "will", "can", "presumes", "should", "may" and, in each case, negations thereof or other similar expressions. The forward-looking statements in this press release are based on different assumptions which, in several cases, are based on additional assumptions. Even if the Company considers the assumptions which are reflected in these forward-looking statements to be true, it cannot be guaranteed that they will in fact occur or that they are correct. Given that these assumptions are based on assumptions or estimates and that they are subject to risks and uncertainties, the actual result may, for many reasons, substantially deviate from what is stated in the forward-looking statements. Such risks, uncertainties, eventualities, and other significant factors may lead to the actual events deviating substantially from the expectations that have been explicitly or implicitly provided for under this press release through the forward-looking statements. The Company does not guarantee that the assumptions which the forward-looking statements in this press release are based on are correct, and a reader of this press release should not unduly rely on the forward-looking statements contained herein. The information, opinions, and forward-looking statements which are either explicitly or implicitly presented herein, are only provided as of the day of this press release and may be subject to change. Neither the Company nor anyone else undertakes to oversee, update, confirm or provide public notification in respect of any change of any forward-looking statement for the purpose of reflecting the actual events or circumstances which occurs in respect of the content of this press release, unless required by law or Nasdaq First North Growth Market's rules for issuers. [1] The exact amount is SEK 48,562,360.[2] Dementia facts and figures. Alzheimer's Disease International. hämtad 2023-10-12.[3] Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging; Rioghna R. Pittock et al; Neurology, 2023;101:e1837-e1849. .[4] Preclinical evidence for anti-inflammatory and immunomodulatory effects of NeuroRestore ACD856, a Trk-PAM in clinical development for the treatment of Alzheimer's disease, Parrado-Fernández, C., CTAD poster, October 2024. se/en/wp-content/uploads/sites/2/2024/10/ Dahlhamer, J. et. al., Prevalence of Chronic Pain and High-Impact Chronic Pain Among Adults - United States, 2016.[6] Leadley, R. M. et. al., Journal of Pain & Palliative Care Pharmacotherapy Volume 26,2012 issue 4, Chronic Diseases in the European Union: The Prevalence and Health Cost Implications of Chronic Pain, 2012. For more information, please contact Martin Jönsson, CEOTel: +46 707 86 94 About AlzeCure Pharma AB (publ) AlzeCure ® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore ® , Alzstatin ® and Painless. NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease and is being prepared for phase 2. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain with positive phase 2 results, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development through an early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies. FNCA Sweden AB is the company's Certified Adviser. For more information, please visit . This information is information that AlzeCure Pharma is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-06-16 08:00 CEST. Attachments AlzeCure carries out a rights issue of approximately SEK 48.5 million SOURCE: AlzeCure Pharma View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
07-04-2025
- Health
- Yahoo
New Data Bolstering the Anti-inflammatory Effect of NeuroRestore ACD856 Presented at Alzheimer's Conference
STOCKHOLM, SE / / April 7, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, announced today that the company's presentation at the AD/PD 2025 scientific conference is now available in its entirety on the company's website. The presentation includes new preclinical data with the company's lead drug candidate NeuroRestore ACD856, which is being developed with a focus on Alzheimer's disease. The presentation, titled Further investigation on the immunomodulatory and anti-inflammatory effects of NeuroRestore ACD856, a Trk-PAM in clinical development for the treatment of Alzheimer's disease , which was presented at the International Conference on Alzheimer's, Parkinson's and Related Neurological Diseases (AD/PD 2025) in Vienna, Austria, was held by Dr. Gunnar Nordvall, Head of Chemistry at AlzeCure Pharma. The new preclinical data presented show that ACD856, the lead drug candidate in the NeuroRestore project, significantly reduced levels of several well-known inflammatory markers such as IL-6, PGE2 and COX in a preclinical model of neuroinflammation. The model uses so-called microglia, which are immune cells found in the brain and are thought to play a very important role in the disease process in Alzheimer's disease. "These new findings suggest that ACD856, along with its memory-enhancing and disease-modifying effects, may reduce neuroinflammation, a critical factor in the development of Alzheimer's, which could further delay the disease's progression," said Gunnar Nordvall, Head of Chemistry at AlzeCure Pharma. ACD856 is a positive modulator of both NGF/TrkA and BDNF/TrkB-mediated signaling that has been shown in preclinical studies to enhance communication between neurons and improve cognitive function, including learning and memory. Previous preclinical results from AlzeCure show that the compound also has neuroprotective, anti-inflammatory and disease-modifying effects in several different models. The unique pharmacological mechanism of NeuroRestore also enables multiple indications, such as Alzheimer's and Parkinson's disease, but also depression. ACD856 is a first-in-class drug candidate for Alzheimer's disease and is now being prepared for upcoming Phase II clinical trials in patients, which is financially supported by the European Innovation Council, via an EIC Accelerator grant of €2.5m. "These are very good results that add to the previous positive data for NeuroRestore ACD856 and further strengthen our commercial opportunities for this promising compound in areas with very high medical needs," said Martin Jönsson, CEO of AlzeCure Pharma AB. The abstract and the poster are available on AlzeCure's website ( ). For more information, please contact Martin Jönsson, CEOTel: +46 707 86 94 About AlzeCure Pharma AB (publ) AlzeCure ® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore ® , Alzstatin ® and Painless. NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease and is being prepared for phase 2. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain with positive phase 2 results, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development through an early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies. FNCA Sweden AB is the company's Certified Adviser. For more information, please visit . About NeuroRestoreNeuroRestore is a platform of symptom-relieving drug candidates for disease states in which cognitive ability is impaired, e.g. Alzheimer's Disease, sleep apnea, traumatic brain injury and Parkinson's disease. NeuroRestore stimulates several important signaling pathways in the brain, which among other things leads to improved cognition. Preclinical studies with NeuroRestore have shown that AlzeCure's drug candidates enhance communication between the nerve cells and improve cognitive ability. The NeuroRestore substances are so called Trk-PAMs which stimulate specific signaling pathways in the central nervous system known as neurotrophins, the most well-known being NGF (Nerve Growth Factor) and BDNF (Brain Derived Neurotrophic Factor). The levels of NGF and BDNF are disturbed in several disease states and the signaling is reduced. The impaired function impairs communication between the synapses, i.e. the contact surfaces of the nerve endings, as well as reducing the possibility of survival for the nerve cells, which gives rise to the cognitive impairments. Neurotrophins play a crucial role for the function of nerve cells, and a disturbed function of BDNF has a strong genetic link to impaired cognitive ability in several different diseases, such as Alzheimer's, Parkinson's disease, traumatic brain injury and sleep disorders. There is also a link between BDNF signaling and depression, something that has been further strengthened in recent years. In addition to cognitive-enhancing effects, new preclinical data also show that NeuroRestore substances have a positive effect on mitochondrial function and display neuroprotective as well as anti-inflammatory effects, which could indicate potential disease-modifying effects. The leading drug candidate in the platform, ACD856, has recently completed clinical phase I studies and demonstrated positive effects there that support continued development of the program and are being prepared for phase 2. Read more at: About Alzheimer's diseaseAlzheimer's disease is the most common form of dementia, affecting approximately 55 million people worldwide, and the number is estimated to triple in the next 30 years if nothing is done. Alzheimer's disease is a lethal disorder that also has a large impact on both relatives and the society. Today, preventive and disease modifying treatments are missing. The main risk factors to develop Alzheimer's are age and genetic causes. Even though the disease can start as early as between 40 and 65 years of age, it is most common after 65 years. Significant investments in Alzheimer research are being made because of the significant unmet medical need and the large cost of this disease for healthcare and society. The total global costs for dementia related diseases are estimated to about 1,300 billion USD globally in 2019. Given the lack of both effective symptomatic treatments and disease modifying treatments, including preventive treaments, the need for new effective therapies is acute. The few approved drugs on the European market today have only a limited symptomatic effect and can produce dose limiting side effects. A disease modifying treatment for Alzheimer's disease is estimated to reach more than $15 billion in annual sales. In Sweden, approximately 100,000 people suffer from Alzheimer's disease with a healthcare cost of about SEK 63 billion yearly, which is more than for cancer and cardiovascular diseases combined. Image Attachments Martin Jönsson And Gunnar Nordvall AlzeCure Pharma Attachments New data bolstering the anti-inflammatory effect of NeuroRestore ACD856 presented at Alzheimer's conference SOURCE: AlzeCure Pharma View the original press release on ACCESS Newswire Sign in to access your portfolio
Yahoo
01-04-2025
- Business
- Yahoo
AlzeCure Pharma to present at Redeye Theme: Alzheimer & Parkinsons on April 8
STOCKHOLM, SE / / April 1, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, today announced that the company is participating at Redeye Theme: Alzheimer & Parkinsons on April 8, 10:55am, when CEO Martin Jönsson presents the company and its pipeline within Alzheimer's. Watch the livestream via The session will also be available afterwards on AlzeCure's company page at Redeye , and on AlzeCure's website . Time: 10.30am - 12.00pm CET, April 8Venue: Redeye, Mäster Samuelsgatan 42, Stockholm, Sweden For more information, please contact Martin Jönsson, CEOTel: +46 707 86 94 About AlzeCure Pharma AB (publ) AlzeCure ® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore ® , Alzstatin ® and Painless. NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease and is being prepared for phase 2. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease and comprises two drug candidates. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain with positive phase 2 results, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development through an early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies. FNCA Sweden AB is the company's Certified Adviser. For more information, please visit . Image Attachments Martin Jönsson CEO AlzeCure Pharma Attachments AlzeCure Pharma to present at Redeye Theme: Alzheimer & Parkinsons on April 8 SOURCE: AlzeCure Pharma View the original press release on ACCESS Newswire Sign in to access your portfolio
